Overall, these results reveal a significant prevalence of USP12 downregulation in human NSCLC and suggest that USP12 downregulation may represent a convergent response to the signals driven by oncogenic mutations or their surrogates in tumour cells. The gene discussed is USP12; the disease is non-small cell lung carcinoma.